Eli Lilly secures up to $1.12 billion agreement with Seamless Therapeutics to pursue gene-editing treatments for hearing loss
Eli Lilly has entered into a collaboration worth as much as $1.12 billion with Germany-based Seamless Therapeutics to develop and commercialize gene-editing therapies aimed at certain forms of hearing loss. The arrangement grants Lilly access to Seamless' proprietary enzyme platform, which engineers programmable recombinases designed to make large,…